Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R C Donehower

Showing results (101-110 of 129) with videos related to

Pageof 13
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weeklyD J Stewart, R C Donehower, E A Eisenhauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 1996
Tissue and tumor distribution of C-penclomedine in ratsS O'Reilly, N R Hartman, S A Grossman, et al.
Cancer Research|June 1, 1990
Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazoleA Hantel, R C Donehower, E K Rowinsky, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1992
Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancerL B Grochow, E K Rowinsky, R Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limitingE K Rowinsky, V Chaudhry, A A Forastiere, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 8, 2001
Tumor targeting by conjugation of DHA to paclitaxelM O Bradley, C S Swindell, F H Anthony, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion scheduleM A Carducci, J Gilbert, M K Bowling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doubletM J Kennedy, M L Zahurak, R C Donehower, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemiaE K Rowinsky, A Adjei, R C Donehower, et al.
Cancer Research|April 15, 1993
Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humansE K Rowinsky, D A Noe, D S Ettinger, et al.
Pageof 13

Showing results (101-110 of 129) with videos related to

Sort By:
Pageof 13
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weeklyD J Stewart, R C Donehower, E A Eisenhauer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 1996
Tissue and tumor distribution of C-penclomedine in ratsS O'Reilly, N R Hartman, S A Grossman, et al.
Cancer Research|June 1, 1990
Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazoleA Hantel, R C Donehower, E K Rowinsky, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1992
Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancerL B Grochow, E K Rowinsky, R Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limitingE K Rowinsky, V Chaudhry, A A Forastiere, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|August 8, 2001
Tumor targeting by conjugation of DHA to paclitaxelM O Bradley, C S Swindell, F H Anthony, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2001
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion scheduleM A Carducci, J Gilbert, M K Bowling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doubletM J Kennedy, M L Zahurak, R C Donehower, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemiaE K Rowinsky, A Adjei, R C Donehower, et al.
Cancer Research|April 15, 1993
Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humansE K Rowinsky, D A Noe, D S Ettinger, et al.
Pageof 13